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Abstract
Innate immune restriction factors represent important specialized barriers to zoonotic transmission of viruses. Significant
consideration has been given to their possible use for therapeutic benefit. The apolipoprotein B mRNA editing enzyme
catalytic polypeptide 3 (APOBEC3) family of cytidine deaminases are potent immune defense molecules capable of
efficiently restricting endogenous retroelements as well as a broad range of viruses including Human Immunodeficiency
virus (HIV), Hepatitis B virus (HBV), Human Papilloma virus (HPV), and Human T Cell Leukemia virus (HTLV). The best
characterized members of this family are APOBEC3G (A3G) and APOBEC3F (A3F) and their restriction of HIV. HIV has evolved
to counteract these powerful restriction factors by encoding an accessory gene designated viral infectivity factor (vif). Here
we demonstrate that APOBEC3 efficiently restricts CCR5-tropic HIV in the absence of Vif. However, our results also show that
CXCR4-tropic HIV can escape from APOBEC3 restriction and replicate in vivo independent of Vif. Molecular analysis identified
thymocytes as cells with reduced A3G and A3F expression. Direct injection of vif-defective HIV into the thymus resulted in
viral replication and dissemination detected by plasma viral load analysis; however, vif-defective viruses remained sensitive
to APOBEC3 restriction as extensive G to A mutation was observed in proviral DNA recovered from other organs.
Remarkably, HIV replication persisted despite the inability of HIV to develop resistance to APOBEC3 in the absence of Vif.
Our results provide novel insight into a highly specific subset of cells that potentially circumvent the action of APOBEC3;
however our results also demonstrate the massive inactivation of CCR5-tropic HIV in the absence of Vif.
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Introduction
Innate immune restriction factors embody specialized barriers
to zoonotic transmission of viruses. Substantial consideration has
been given to their potential use for therapeutic benefit [1,2]. The
apolipoprotein B mRNA editing enzyme catalytic polypeptide 3
(APOBEC3) family of cytidine deaminases are potent innate
immune defense factors capable of efficiently restricting endoge-
nous retroelements as well as a diverse range of viruses including
Hepatitis B virus, Human Immunodeficiency virus, Human T Cell
Leukemia virus, TT virus, and Human Papilloma virus [3–8].
The best-characterized APOBEC3 family members are the
immune defense molecules APOBEC3G (A3G) and APOBEC3F
(A3F) and their lethal restriction of HIV [5,9]. HIV has evolved to
counteract these powerful restriction factors by encoding an
accessory gene designated viral infectivity factor (vif). In vitro studies
have elegantly shown that in the absence of Vif, A3G and A3F are
encapsidated into nascent virions and deaminate cytosines in the
minus strand of HIV DNA during reverse transcription [10–12].
APOBEC3 deamination of cytosines in the minus strand of the
viral genome occurs at both CC and TC dinucleotide sites,
resulting in GG to AG as well as GA to AA mutations in the
coding strand of the viral genome [10,11,13,14]. APOBEC3
induced G to A mutations at GG dinucleotide sites are exclusively
the result of A3G deamination, while mutations occurring at GA
sites can be caused by multiple APOBEC3 proteins including both
A3F and A3G [10,15]. While studies have demonstrated the
deleterious effects of G to A hypermutation of the HIV genome
[10,16–18], a recent in vitro study showed variable levels of A3G
induced G to A mutations suggesting that A3G may contribute to
viral diversity [19].
In this study, we use humanized mice for the in vivo study of HIV
in the context of a human immune system. Both NSG-hu and
NSG BLT mice are systemically reconstituted with multiple
lineages of hematopoietic cells including T cells, B cells, and
myeloid cells following transplantation with CD34+ hematopoietic
stem cells [20,21]. Additionally, BLT humanized mice are
implanted with human liver and thymic tissue under the kidney
capsule prior to the transplant of autologous CD34+ cells which
results in the development of a bona fide human thymus for T cell
development [21]. Like any other model for HIV/AIDS research
humanized mice have several strengths and limitations that have
to be taken into consideration in the development of experimental
plan. Two recent review articles cover this area in significant detail
[22,23]. Despite their limitations humanized mouse models have
previously been used for the study of HIV transmission,
pathogenesis, prevention, therapy and latency/eradication
[20,24–28]. Here we first demonstrate the highly effective
inactivation of CCR5-tropic HIV-1 by APOBEC3 when unob-
structed by a functioning vif in vivo after intravenous infection.
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Secondly, we demonstrate that if injected directly into the thymus,
vif-defective viruses can replicate escaping absolute APOBEC3
restriction.
Results
Mutations in vif do not affect virus replication in the
absence of APOBEC3
To confirm that the mutations disrupting vif do not have a
detrimental effect on the replicative capacity of HIV-1JR-CSF, we
generated a CCR5 expressing permissive cell line (CEM-SS
CCR5) and infected them with wild-type HIV-1JR-CSF or isogenic
viruses containing either an irreparable deletion in vif
(HIVJR-CSFDvif) or a one base insertion in vif (HIVJR-CSFvifFS).
Replication of both vif-defective viruses was equal to that of wild-
type in permissive cells, confirming that the disruption of vif did
not have a deleterious effect on HIV-1 in the absence of
APOBEC3 (Figure 1A).
vif-deleted CCR5 tropic HIV-1 administered intravenously
is rapidly restricted by APOBEC3 in vivo
To assess the in vivo effectiveness of APOBEC3 restriction of
HIV, we intravenously infected NSG-hu mice with wild-type HIV-
1JR-CSF (a T-cell CCR5-tropic primary isolate) or HIVJR-CSFDvif.
As early as one week after intravenous infection, widespread
replication of wild-type virus was detected as HIV DNA was
amplified from every tissue analyzed (Figure 1B). In contrast the
vif-defective virus did not sustain replication in humanized mice; as
viral DNA was sparsely present (Figure 1B). Notably, HIVJR-
CSFDvif DNA could only be amplified from one organ from each
infected mouse suggesting that an extremely low number of
infected cells were present. Analysis of the viral DNA sequence
from the animals revealed that HIV DNA from mice infected with
wild-type virus had no mutations, whereas viral DNA from the
HIVJR-CSFDvif infected mice had numerous G to A mutations
consistent with APOBEC3 induced restriction (Figure 1C). The
limited number of tissues with cells harboring G to A mutated
HIVJR-CSFDvif DNA one week after exposure suggests that
APOBEC3 restriction of vif-defective HIV occurs rapidly in vivo.
APOBEC3 restriction of CCR5 tropic in the absence of vif
While evidence of APOBEC3 restriction of vif-deficient HIV is
observed early after infection, we next determined whether
HIVJR-CSFDvif could develop resistance to APOBEC3 and
replicate systemically. To address this, we infected humanized
mice (n = 8) intravenously with HIVJR-CSFDvif and monitored
them for plasma viral load. Longitudinal analysis demonstrated
that HIVJR-CSFDvif restriction by APOBEC3 is absolute, as no
viral RNA was present in the plasma of the mice at any time point
in contrast to infection with wild-type HIVJR-CSF (Figure 2A). No
revertants or complementary changes arose that restored the
ability of HIVJR-CSFDvif to replicate. In contrast to the widespread
presence of viral DNA in all tissues analyzed after wild-type HIV
infection, the extremely limited replication of HIVJR-CSFDvif was
confirmed by the absence of HIV DNA in tissues obtained from 4/
8 infected mice, and the presence of lethally mutated viral DNA in
only a few tissues of the other four animals (Figure 2B). To
determine the extent of APOBEC3 hypermutation in the HIVJR-
CSFDvif provirus, we analyzed the sequences for G to A mutations
at GG, GA and GY dinucleotide sites which are the targets of the
APOBEC3 proteins. We found that 25–65% of the GG sites had
been mutated with additional (albeit fewer) mutations present at
GA sites, demonstrating extensive APOBEC3 hypermutation to
lethally restrict HIVJR-CSFDvif (Figure 2C). Analysis of the
mutational profile in the HIVJR-CSFDvif DNA from the mice showed
that 84% of all the G to A mutations occurred at GG dinucleotide
sites whereas only 15% of mutations were present at GA sites and
only 1% occurred at GY sites (Figure 2D). Taken together, these
results demonstrate that HIVJR-CSFDvif is unable to overcome the
loss of Vif and is lethally restricted by APOBEC3 in vivo.
Human APOBEC3 exerts a strong selective pressure on
HIV-1 in vivo
To evaluate the selective pressure exerted by APOBEC3 on
HIV in vivo, we used a mutant isogenic virus containing a one base
insertion in vif (HIVJR-CSFvifFS) to intravenously infect 16
humanized mice representing 7 different human donors. Consis-
tent with our previous results, in 10/16 mice intravenously
infected with HIVJR-CSFvifFS there was no evidence of virus
replication as determined by the absence of viral RNA in the
plasma (Figure 3A). However, in the remaining six mice the virus
was able to replicate to levels similar to those observed with the
wild-type virus (Figure 3A). One salient aspect noted was the
almost complete absence of APOBEC3 mutations in viral RNA
samples obtained from the plasma from these six mice. Molecular
analysis of viral sequences from the peripheral blood from these
mice demonstrated that in all six cases a one-nucleotide deletion
had occurred that fully restored the vif open reading frame (ORF)
highlighting the extreme selective pressure APOBEC3 exerts on
HIV in vivo to restore Vif activity or be lethally mutated. Two
important issues that should be noted are 1) the virus used for
these experiments was generated via transient transfection of 293T
cells creating a uniform inoculum and 2) that this repair mutation
occurring in vivo is not at a putative APOBEC3 site and therefore it
is most likely is a result of a mutation occurring during reverse
transcription.
We then analyzed viral DNA from the tissues of all 16 mice
exposed to HIVJR-CSFvifFS. In multiple tissue samples from four of
the aviremic mice we found no evidence of HIV DNA. In similar
samples from six other aviremic mice only low levels of heavily
mutated HIV DNA was present in a few tissues (30–60% of the
Author Summary
The APOBEC3 family of proteins is a potent cellular
defense mechanism capable of restricting a broad range
of viruses including HIV. HIV requires a critical accessory
protein, Vif, which targets APOBEC3 for degradation
thereby shielding its genome from lethal mutagenesis.
Previous in vitro studies have shown that in the absence of
Vif, HIV can be hypermutated by APOBEC3. This potent
restrictive function of APOBEC3 has generated strong
interest in developing therapeutics based on the APO-
BEC3/Vif axis. Here we demonstrate in vivo that CCR5-
tropic HIV can be efficiently restricted by APOBEC3.
However, our results also show that CXCR4-tropic HIV
can replicate independent of Vif and escape lethal
restriction by APOBEC3. Specifically, we show that thymo-
cytes have reduced expression of A3G and A3F and that
direct injection of vif-defective HIV into the thymus results
in viral replication and dissemination. Despite continued
Vif-independent HIV replication, the virus remained sensi-
tive to APOBEC3 mutagenesis and was rapidly restricted in
tissues with higher A3G and A3F expression. Our results
provide novel insight into the restriction of HIV in vivo and
identify a potentially significant defect in the innate
immune defenses that protect the host cell from patho-
gens.
APOBEC3 Restriction of HIV In Vivo
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GG dinucleotide sites mutated) (Figure 3B and 3C). The
mutational profile of the viral DNA from these animals again
showed a preference for GG sites accounting for 87% of all
mutations (Figure 3D). In sharp contrast, in mice where the vif
ORF was restored virtually intact viral DNA was present in every
tissue analyzed, highlighting the strong selective pressure exerted
by APOBEC3 on HIV (Figure 3B and 3C). The lack of G to A
mutations in the vif-restored viral genome suggested that the virus
had evaded APOBEC3 restriction until restoring vif.
HIV-1JR-CSFvifFS restores vif following direct injection into
the thymus
The stochastic nature of vif ORF restoration may reflect its
occurrence in a specific anatomical location(s). Therefore we
directly injected 96104 TCIU of HIVJR-CSFvifFS into the spleen,
liver, lung or human thymic implant of separate humanized mice.
Evidence of viral replication in peripheral blood was exclusively
found when HIVJR-CSFvifFS was injected directly into the thymus
(Figure 4A). In this case, sequence analysis of vif showed a one base
deletion restoring Vif expression. Injection of the virus into the
spleen, liver, or lung resulted in absolute restriction with no
viremia and no residual viral DNA present in any tissue (Figure 4A
and 4B)
To determine if restoration of the vif ORF following thymic
injection was non-random, we increased the virus inoculum four-
fold and repeated the infection, using 3.66105 TCIU of HIVJR-
CSFvifFS injected into the same set of tissues. Again evidence of
HIV replication was only observed after intrathymic exposure with
3/3 mice that received the virus directly into the thymus becoming
viremic (Figure 4A). Strikingly, despite the high virus inoculum
injected directly into the spleen, liver, or lung no evidence of virus
replication was observed (Figure 4A). When tissues from these
animals were analyzed, we found that only one mouse, FS24, had
viral DNA present (Figure 4B) and that it had all been lethally
mutated by APOBEC3 (Figure 4C and 4D). These results
demonstrate that transient HIVJR-CSFvifFS replication and subse-
quent vif restoration specifically occurs following a direct thymic
exposure. Furthermore, the potent antiretroviral activity of
APOBEC3 is highlighted by the absolute restriction of HIVJR-
CSFvifFS when the virus is injected into other tissues.
APOBEC3G and APOBEC3F expression is reduced in the
thymus
Since the reversion of the vif ORF specifically occurred
following injection of the virus into the thymus, we next
determined whether A3G and A3F expression was lower in the
thymus compared to other tissues. We tested this by comparing
A3G and A3F mRNA levels in purified thymocytes (of which
.90% are CD4+) with those in CD4+ cells isolated from other
tissues in humanized mice. Our results show that thymocytes
Figure 1. Human APOBEC3 rapidly restricts vif-deleted HIV-1JR-
CSF in vivo. (A) Replication of HIVJR-CSF, HIVJR-CSFDvif, and HIVJR-CSFvifFS
in CEM-SS cells expressing CCR5 (CEM-SS CCR5). Culture supernatant
was assayed for p24Gag by ELISA at three day intervals to determine the
replication kinetics of the mutant viruses. (B) Nested PCR amplification
of viral DNA from the tissues obtained one week post-exposure from a
representative NSG-hu mouse infected with 96104 TCIU of wild-type
HIV-1JR-CSF (WT1) or from three mice infected with 3.6610
5 TCIU of
HIVJR-CSFDvif (indicated as D1–3). (C) Highlighter sequence analysis of 7
wild-type and 3 Dvif HIV DNA sequences. Amplified viral DNA from
panel A showed no APOBEC3 induced mutations in HIVJR-CSF (WT1 all
sequence from tissues is shown together). In contrast, viral DNA from all
positive tissues obtained from HIVJR-CSFDvif infected mice had G to A
(green lines) and/or C to T mutations (red lines). HIV-1JR-CSF nucleotide
numbers are indicated at the bottom.
doi:10.1371/journal.ppat.1003242.g001
APOBEC3 Restriction of HIV In Vivo
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express 4–8 fold less A3G mRNA and 2.5–3.5 fold less A3F
mRNA than human CD4+ cells isolated from the spleen, liver or
lung (Figure 5A and Figure S1). Furthermore, no difference in
A3G or A3F mRNA expression was found in thymocytes from
humanized mice or human thymus. Additionally, A3G in
thymocytes was found to be 3–4 fold lower compared to human
peripheral blood mononuclear cells (PBMC) by both mRNA and
protein expression (Figure 5A and 5B). These results are consistent
with the observation that vif reversion specifically occurs following
thymic injection of HIVJR-CSFvifFS and suggests that the thymus
may support Vif-independent HIV replication.
Based on our observations of reduced A3G and A3F expression
in thymocytes and reversion of the vif ORF exclusively occurring
with thymic exposure, we considered the possibility that a direct
injection of HIVJR-CSFDvif (the virus containing a non-revertible
deletion in vif) into the thymus would result in Vif-independent
replication. HIV RNA was transiently observed in the plasma of
2/6 mice following thymic infection with this virus (Figure S2).
This low level of replication in some mice is consistent with the
results presented above with frame shift containing HIVJR-CSFvifFS
(Figure 4A), in which the virus had restored the vif ORF and was
able to replicate unimpeded by APOBEC3 after reversion. These
results show that recovery of Vif activity is necessary for ongoing
replication and viral dissemination by vif-defective HIVJR-CSF.
Vif-independent CXCR4-tropic HIV-1 replication is
sustained in vivo
We hypothesized that the lack of robust and sustained
replication of HIVJR-CSFDvif following direct thymic infection
could be due to limited CCR5 expression in the thymus, as ,5%
of thymocytes express CCR5 whereas 30–40% of thymocytes
express CXCR4 [29–31]. We therefore introduced the deletion
described above into the vif ORF of HIV-1LAI, a CXCR4-tropic
virus (HIVLAIDvif) and confirmed that the disruption of vif did not
affect the ability of the virus to replicate in the absence of
APOBEC3 (Figure S3). We tested our hypothesis by directly
injecting HIVLAIDvif into the thymus of four humanized mice.
Viremia was present in 4/4 animals inoculated in this manner
Figure 2. vif-deleted HIV-1JR-CSF does not overcome APOBEC3 restriction in vivo. (A) Longitudinal analysis of plasma viral load in humanized
mice intravenously infected with 96104 TCIU of wild-type HIV-1JR-CSF or 3.6610
5 TCIU of HIVJR-CSFDvif. (B) Detection of HIV DNA (+) by nested PCR
from the tissues of humanized mice in panel A. Negative tissues (2) yielded no amplified viral DNA using two independent nested PCR primer sets
targeting separate regions of the viral genome. N/A = not analyzed. (C) Percentage of putative APOBEC3 mutation sites (GG, GA, GY) that were
mutated in 17 viral DNA sequences amplified from the tissues of infected mice. Viral DNA from mice infected with HIVJR-CSFDvif had 25%–65% of GG
sites mutated. (D) G to A mutational profile of all viral DNA from mice infected with HIVJR-CSFDvif. Percentages indicate the proportion of G to A
mutations occurring at GG (blue), GA (red), or GY (black) sites. D4-D8, WT2-WT3, NSG-hu mice. D9-D11, NSG-BLT mice.
doi:10.1371/journal.ppat.1003242.g002
APOBEC3 Restriction of HIV In Vivo
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(Figure 6A). In contrast, when HIVLAIDvif was directly injected
into the spleen, liver, or lung of an additional 3 animals viral
replication was absolutely restricted (Figure 6A). These results
further demonstrate that Vif-independent HIV replication can be
sustained following exposure into the thymus but is vigorously
restricted in other tissues. Additionally, when HIVLAIDvif was
injected intravenously, sustained levels of viral replication were
observed in the plasma of humanized mice; however this
replication was lower relative to the parental virus (Figure 6B).
Remarkably, unlike wild-type HIVLAI which rapidly depletes
Figure 3. Human APOBEC3 exerts a strong selective pressure on HIV-1JR-CSF containing a frameshift in vif. (A) Plasma viral load analysis
in humanized mice intravenously infected with 96104 or 3.66105 TCIU of HIVJR-CSFvifFS. Viral RNA was not detected in the plasma (circles, n = 10)
unless the vif ORF is restored (triangles, n = 6). The appearance of plasma viremia was delayed by 4 weeks in one of these mice. (B) Detection of HIV
DNA (+) by nested PCR from the tissues of humanized mice intravenously infected with HIVJR-CSFvifFS. Negative tissues (2) yielded no amplified viral
DNA using two independent nested PCR primer sets targeting separate regions of the viral genome. Viral DNA is sparsely present in tissues from mice
where vif was not restored (indicated as FS1–10). In contrast, all tissues analyzed from the six mice where vif was restored had viral DNA present
(FS11–16). N/A = not analyzed. (C) Percentage of putative APOBEC3 mutation sites (GG, GA, GY) that were mutated in 76 viral DNA sequences
amplified from the tissues of HIVJR-CSFvifFS infected mice where vif was not restored (40% of all GG sites mutated) or mice where vif was restored (no
hypermutation). Data represent mean +/2 SEM. (D) G to A mutational profile of all viral DNA from mice infected with HIVJR-CSFDvif. Percentages
indicate the proportion of G to A mutations occurring at GG (blue), GA (red), or GY (black) sites. FS1–FS9, FS11–FS14, NSG-hu mice. FS10, FS15–FS16
NSG-BLT mice.
doi:10.1371/journal.ppat.1003242.g003
APOBEC3 Restriction of HIV In Vivo
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peripheral blood CD4+ T cells, infection with HIVLAIDvif did not
deplete CD4+ T cells in the periphery despite sustained viral
replication (Figure 6C). Sequencing of viral RNA obtained from
the plasma of HIVLAIDvif infected mice showed significantly fewer
G to A mutations compared to the same region of viral DNA
isolated from PBMC, suggesting that the infection was likely being
sustained in cells with lower APOBEC3 expression (Figure 6D).
Consistent with these results, HIVLAIDvif DNA was abundant in
the tissues of intrathymically or intravenously exposed mice while
direct exposure into the spleen, liver, or lung resulted in viral DNA
sparsely present in the organs (Figure 6E). Since this virus could
not restore Vif expression, its viral DNA had G to A mutations;
however, consistent with the low expression of A3G and A3F in
the thymus (Figure 5A, 5B and S1), significantly fewer G to A
Figure 4. Restoration of vif occurs only following direct virus injection into the thymus. (A) Longitudinal analysis of plasma viral load in
NSG-BLT humanized mice infected with HIVJR-CSFvifFS directly into the human thymic implant, spleen, liver, or lung. Solid symbols represent mice
infected with a low dose of virus (96104 TCIU), open symbols represent the high dose infection (3.66105 TCIU). (B) Detection of HIV DNA (+) by
nested PCR from the tissues of humanized mice in panel A. Negative tissues (2) yielded no amplified viral DNA using two independent nested PCR
primer sets targeting separate regions of the viral genome. (C) Percentage of putative APOBEC3 mutation sites (GG, GA, GY) that were mutated in 44
viral DNA sequences amplified from the tissues of mice injected with HIVJR-CSFvifFS. Mice injected into the thymic implant had no GG to AG mutations
in any tissue whereas HIV DNA from four tissues of mouse FS24 injected into the spleen is hypermutated. (D) G to A mutational profile of all viral DNA
from mouse FS24 which failed to restore the vif ORF. Percentages indicate the proportion of G to A mutations occurring at GG (blue), GA (red), or GY
(black) sites.
doi:10.1371/journal.ppat.1003242.g004
APOBEC3 Restriction of HIV In Vivo
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mutations were present in viral DNA amplified from the thymus
when compared to the same region of the viral DNA amplified
from other organs (Figure 6F). Analysis of the mutational profile in
the HIVLAIDvif DNA from the mice showed that 86% of all the G
to A mutations occurred at GG dinucleotide sites (Figure 6G). The
presence of hypermutated provirus in several tissues suggests that
the HIV was not able to develop resistance to APOBEC3 by
second site mutations in the absence of vif, but was instead
persisting in a pool of cells that permitted replication (Figure 7).
Taken together, these results demonstrate that HIV can sustain
replication independent of vif escaping APOBEC3 restriction in
vivo.
Discussion
Our results demonstrate evidence of vif-independent replication
of HIV in an in vivo setting. The observation that infection with
CCR5 tropic HIV is rapidly extinguished in the absence of vif
while CXCR4 tropic HIV lacking vif can sustain replication
suggests that vif-independent HIV replication is occurring in a
location with a paucity of cells expressing CCR5, such as the
thymus where ,5% of cells express CCR5 while a far greater
number of cells (30–40%) express CXCR4 [29–31]. Consistent
with this observation, direct injection of vif-deficient HIV into
organs resulted in detectable viral replication only following
thymic infection. Remarkably, reversion of the vif ORF with
HIVJR-CSFvifFS occurred in 100% of thymic exposures while being
absolutely restricted when injected into all other organs,
highlighting the potent antiretroviral activity of APOBEC3.
Interestingly, despite the strong selective pressure applied by
APOBEC3, we did not observe any evidence of vif-defective HIV-
1JR-CSF altering its coreceptor usage to take advantage of the lower
A3G and A3F expression in the thymus. Coreceptor switching is a
complicated process involving multiple mutations in envelope that
occurs over a period of years in patients [32]. During their short
lifespan, coreceptor switching is not common in humanized mice
and has only been reported in a single mouse [33].
Our results demonstrate massive inactivation of CCR5-tropic
HIV-1 when the protective effects of Vif are absent. These results
are consistent with previously published work by Sato et. al. [34].
Under their experimental conditions, these investigators found
that vif-defective CCR5-tropic HIV did not replicate at all in
humanized mice. Replication of HIV-1 with a functional vif gave a
different result. In this case, there was a low level of G to A
mutation in both A3G and A3F contexts in viral DNA sequences
[34]. Thus, these authors confirmed in the humanized mouse
model the early observations of the occasional occurrence of
hypermutation of HIV-1 isolated from patients [35–38].
Analysis of HIV DNA in aborted infections for G to A
hypermutation, the hallmark of APOBEC3 restriction, demon-
strated that when HIV DNA was present, there was an
overwhelming prevalence of mutations at GG dinucleotide sites
indicating that in the absence of vif A3G is the dominant HIV
restricting factor in vivo [10–12]. This conclusion is further
supported by two recent papers using stably expressed A3F or
gene targeting to create null mutants to systematically disrupt the
individual APOBEC3 proteins that have elegantly demonstrated
that A3G is the APOBEC3 family member that induces the
preponderance of GG to AG mutations in vif-deficient HIV DNA
[15,39]. One substantial benefit of A3G restriction is that the
mutation of GG to AG can be highly effective in inactivating viral
genes because of the conversion of tryptophan codons (TGG) to
stop codons (TAG, TGA, or TAA).
The lower level of GA to AA mutations that we observed
suggests a contributory role for A3F in the overall level of G to A
mutations we observed. The impact of A3F remains unclear
however since the specificity of A3G for the GG context is not
absolute and some of the GA to AA mutations we observed may
have been created by A3G. A role for A3F in HIV restriction has
been questioned recently but this issue remains unresolved in vivo
[39,40]. Future experiments with humanized mice will address this
question.
The results presented here demonstrate that in vivo HIV fails to
develop second-site mutations to compensate for the absolute loss
of vif to overcome A3G induced mutation, which is in contrast to
observations made with in vitro systems with ectopically expressed
A3G [41,42]. This potent restriction of HIV in vivo is not observed
by inactivation of other HIV-1 accessory genes [43,44]. To survive
in vivo in the absence of vif, HIV relies on target cells with reduced
A3G expression in which it can replicate as shown by the lack of G
to A hypermutation in the cell free virus despite the abundance of
G to A mutations present in viral DNA in several tissues with high
levels of A3G expression. Our analysis CD4+ cells identified
thymocytes as a cell population that has reduced A3G expression.
Previous analysis of A3G expression from whole tissues did not
identify thymocytes as having reduced A3G; however these results
Figure 5. APOBEC3G expression is reduced in the thymus. (A)
Human A3G mRNA levels from human PBMC (n = 7), human thymus
(n = 6), NSG-BLT humanized mouse thymus (n = 18), and CD4+ cells from
NSG-BLT humanized mouse lung (n = 6), spleen (n = 7), liver (n = 7) were
determined using qRT-PCR and normalized to human TATA Box binding
protein. Hatched bars represent human cells; open bars represent
humanized mouse cells. NS = not significant, *** p,0.01 by one way
ANOVA with Bonferroni’s posttest. Data represent mean +/2 SEM. (B)
Immunoblot for human A3G and GAPDH from human PBMC and cells
from human and humanized mouse thymus. Numbers represent A3G
normalized to GAPDH compared to human PBMC which is set to 1.
doi:10.1371/journal.ppat.1003242.g005
APOBEC3 Restriction of HIV In Vivo
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Figure 6. Sustained Vif-independent replication of CXCR4 tropic HIV-1. (A) Plasma viral load was monitored in NSG-BLT humanized mice
infected with 3.66105 TCIU HIVLAIDvif directly into the human thymic implant, spleen, liver, or lung. Direct injection of HIVLAIDvif into the thymus
resulted in plasma viremia in 4/4 infections. (B) Longitudinal analysis of plasma viral load in humanized mice infected intravenously with 3.66105 TCIU
APOBEC3 Restriction of HIV In Vivo
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are difficult to interpret because of the lower percentage of CD4+
cells in organs other than the thymus [45,46]. Furthermore, the
significance of A3G expression levels in the modulation of both
wild-type and vif-deficient HIV replication has been previously
demonstrated in Th1 and Th2 cells [47].
The implications of our findings might not be limited to HIV.
Rather they might also extend to other viruses and retroelements
that are restricted by APOBEC3 proteins [3,4,6–8,48], as they
may also persist as a result of reduced APOBEC3 expression that
affords them the opportunity to replicate. The expansive
restricting activity of the APOBEC3 family on endogenous and
exogenous retroviruses serves to illustrate the broad therapeutic
implications of our observations. This study also raises an
important issue that must be addressed if the Vif-APOBEC3 axis
is to be used to develop small molecular inhibitors of HIV
replication: the well-documented ability of HIV to develop
resistance to all current antiretroviral drugs. By incorporating
point mutations in the relevant viral genes HIV can develop drug
resistance [49]. Our observation of Vif-independent replication
after direct injection into the thymus are consistent with previous
work in humanized mice [50] and highlight the potential for HIV
to escape the effect of a therapeutic Vif inhibitor [51–53]. The
drug resistant virus would then be capable of systemic dissemina-
tion. However, as with other antiretrovirals, the use of combina-
tion therapy may prevent the emergence of such resistance. The
thymus plays a critical role in HIV infection as it is actively
involved in immune reconstitution following suppression of
viremia with antiretroviral therapy. While this immune reconsti-
tution occurs better in children than in adults, extensive thymic
damage and incomplete virus suppression hinder this process [54–
56].
Finally, it remains to be established if sublethal restriction by
other innate immune defense proteins such as Tetherin, Trim-5-
alpha, SamHD1, etc. could allow the replication of other
pathogenic viruses [1]. Therefore, our discovery has long lasting
implications that provide an alternative view of the dynamic
interplay between endogenous immune restriction factors and the
broad spectrum of pathogens they control.
Materials and Methods
Ethics statement
All animal experiments were conducted following NIH guide-
lines for housing and care of laboratory animals and in accordance
with The University of North Carolina at Chapel Hill (UNC-
Chapel Hill) in accordance with protocols approved by the
institution’s Institutional Animal Care and Use Committee. UNC-
Chapel Hill protocol number 12-170.
Proviral constructs, virus stocks and cell lines
Experiments were performed using the CCR5-tropic primary
isolate HIV-1JR-CSF (accession # M38429) or the CXCR4-tropic
molecular clone HIV-1LAI (accession # K02013) [57,58].
Mutations disrupting vif were made in regions that did not affect
the overlapping 39 terminus of pol or the splice acceptor site of vpr.
A non-revertible 172 nucleotide deletion in the 59 half of HIV-1JR-
CSF vif (HIVJR-CSFDvif) was constructed by deleting nucleotides
5138 to 5309 between the NdeI and NcoI sites. A second HIV-1JR-
CSF with a potentially revertible vif (HIVJR-CSFvifFS) was
constructed by inserting a single adenosine after nucleotide 86 in
vif by site directed mutagenesis. A non-revertible 178 nucleotide
deletion in the 59 half of HIV-1LAIvif (HIVLAIDvif) was constructed
by deleting nucleotides 4708–4885 between the NdeI and PflMI
sites [59]. All constructs were analyzed by direct DNA sequencing
prior to virus production. Virus stocks were generated by
transfecting proviral DNA into 293T cells using Lipofectamine
2000 (Invitrogen) and tissue culture infectious units (TCIU) were
determined using TZM-bl cells essentially as we have previously
reported [24,27,60]. TZM-bl Hela cells and human embryonic
kidney 293T cells were cultured at 37uC, 10% CO2 in Dulbecco’s
Modified Eagle Medium (Sigma) supplemented with 10% fetal
bovine serum, 50 IU penicillin, 50 mg/ml streptomycin and 2 mM
of HIVLAIDvif (n = 7) or 3–9610
4 TCIU of wild-type HIVLAI (n = 6). Data represent mean +/2 SEM. (C) Longitudinal analysis of the percentage of CD4+ T
cells in the peripheral blood of humanized mice infected in panel B. (D) Comparison of the G to A mutation frequency in the viral RNA from the
plasma and the viral DNA from peripheral blood cells from mice intravenously infected with HIVLAIDvif. Data represent mean +/2 SEM from 18
sequences, ** p = 0.0066. (E) Detection of HIV DNA (+) by nested PCR from the tissues of BLT humanized mice in panels A and B. Negative tissues (2)
yielded no amplified viral DNA using two independent nested PCR primer sets targeting separate regions of the viral genome. Direct injection of
HIVLAIDvif into the liver, lung or spleen resulted in limited tissue distribution of viral DNA. (F) Comparison of the G to A mutation frequency in viral
DNA from the thymus compared to viral DNA from other tissues of mice infected intrathymically (n = 4) and intravenously (n = 7) with HIVLAIDvif. Data
represent mean +/2 SEM from 83 sequences. (G) G to A mutational profile of all viral DNA from mice infected with HIVLAIDvif. Percentages indicate
the proportion of G to A mutations occurring at GG (blue), GA (red), or GY (black) sites.
doi:10.1371/journal.ppat.1003242.g006
Figure 7. Model depicting sustained in vivo replication of
HIVLAIDvif. Ongoing viral replication persists in cells with low APOBEC3
(shown in green) with little to no APOBEC3 mutation but infection of
cells expressing high APOBEC3 (shown in blue) leads to hypermutation
of the viral genome, resulting in lethal restriction of HIV. Replication
competent viruses are shown in red, defective virions are shown in
black.
doi:10.1371/journal.ppat.1003242.g007
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L-glutamine (Cellgro). CEM-SS cells were cultured at 37uC,
5%CO2 in RPMI 1640 (Sigma) supplemented with 10% fetal
bovine serum, 50 IU penicillin, 50 mg/ml streptomycin, 2 mM L-
glutamine, and 1 mM sodium pyruvate (Cellgro).
To generate a permissive cell line that can be infected with
CCR5-tropic HIV, CEM-SS cells were transduced with the
retroviral vector pBabe-CCR5 obtained from the NIH AIDS
Research and Reference Reagent Program [61,62]. pBabe-CCR5
and the packaging vector pEQPAM were co-transfected into 293T
cells using Lipofectamine 2000 (Invitrogen). The culture superna-
tants were collected after 48 hours and filtered through a 0.45 mm
filter. Twenty-four well plates were coated with 40 mg of Retro-
nectin (Takara) and then washed with PBS+2% BSA and
incubated twice with 0.5 mL of the vector supernatants for one
hour each. CEM-SS cells (36105) were then incubated in the
vector coated wells overnight at 37uC, 5% CO2. The following
day, the vector supernatant (0.5 mL) was added to the cells
overnight. Transduced cells were selected in complete RPMI
containing 0.5 mg/ml puromycin. Fluorescence activated cell
sorting was used to isolate the CD4HiCCR5Hi population with a
BD FACSAria (Becton-Dickinson), collecting the top 25%.
Viral cultures
CEM-SS cells were used to propagate both wild-type and vif-
deficient HIVLAI while CCR5 expressing CEM-SS cells were used
for spreading infections with both wild-type and vif-deficient
HIVJR-CSF. Cells (1610
6) were infected with virus stocks normal-
ized to p24Gag or tissue culture infectious units in complete RPMI
containing 4 mg/ml polybrene at 37uC, 5% CO2 for 4 hours. The
cells were washed extensively with PBS and cultured at 37uC, 5%
CO2 in complete RPMI. Cell cultures were passaged every three
days and a sample of the culture supernatant was collected for
quantification of viral capsid protein by p24Gag ELISA.
APOBEC3G and APOBEC3F determination in thymocytes
and CD4+ cells
Human CD4+ cells from humanized mouse spleen, liver, or lung
were isolated using magnetic bead sorting (Stem Cell Technologies).
A3G and A3F mRNA expression in cells was analyzed by
quantitative RT-PCR (qRT-PCR) essentially as previously described
[46,47]. Briefly, cellular RNA was extracted using the RNeasy kit
(Qiagen) per the manufacturer’s protocol including the optional
treatment with RNase-free DNase (Qiagen) during extraction. Total
RNA (10 ng) was used as the template in a one-step RT-PCR
reaction with the TaqMan RNA-to-Ct 1 step kit (Applied
Biosystems). Primers for human A3G and A3F mRNA [47] and
for human TATA Box binding protein mRNA (Applied Biosystems)
were used for amplification and human A3G and A3F mRNA levels
were normalized as previously described [46]. A3G protein
determination was performed by disrupting cells in lysis buffer
(50 mM Tris, pH = 8.0, 100 mM NaCl, 25 mM NaF, 25 mM
benzamidine, 20 mM b-glycerophosphate, 2 mM Na3VO2, 3 mM
EDTA, 10% glycerol, and 0.5% IGEPAL-630). Lysates were
centrifuged at 13,0006g for 10 minutes and the supernatant fraction
was prepared for SDS-PAGE gel electrophoresis. Separated proteins
were transferred to nitrocellulose and immunoblotted for human
A3G (NIH AIDS reagent program #9968) [63] and human
GAPDH (Cell Signaling Technology #2118). Protein bands were
quantitated by determining density using ImageJ software (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2009).
in vivo analysis of virus replication
Mice were maintained with the Division of Laboratory Animal
Medicine at the University of North Carolina at Chapel Hill under
specific-pathogen free conditions. Humanized mice (BLT and
NSG-hu) were generated and analyzed for reconstitution with
human hematopoietic cells including human T cells by flow
cytometry essentially as previously described [20,21,24,25,27,28].
Humanized mice were inoculated with 36104 or 96104 TCIU of
wild-type HIV-1LAI, 9610
4 TCIU of wild-type HIV-1JR-CSF,
3.66105 TCIU of HIVJR-CSFDvif or HIVLAIDvif, or 9610
4 or
3.66105 HIVJR-CSFvifFS intravenously by tail vein injection or
into specific organs as indicated in the text. HIV-1 infection of
humanized mice was monitored in peripheral blood by viral load
analysis as previously described [27].
Molecular analysis of HIV-1 infection
Tissues were harvested for evaluation of HIV-1 infection
essentially as previously described [21]. Genomic DNA from
mononuclear cells (56105–56106) from animal tissues was
prepared using QIAamp DNA blood mini columns (Qiagen)
according to the manufacture’s protocol. Viral RNA was isolated
from plasma using QIAamp viral RNA columns (Qiagen)
according to the manufacture’s protocol including an optional
treatment with RNase-free DNase (Qiagen) during extraction and
cDNA was generated using Superscript III Reverse Transcriptase
(Invitrogen). Viral DNA or cDNA was amplified by nested PCR
using the Expand High Fidelity PCR System (Roche).
All PCR primers amplify both HIV-1JR-CSF and HIV-1LAI and
were designed to anneal in regions with the fewest possible putative
APOBEC3 deamination sites to avoid potential primer mismatch
due to APOBEC3 induced mutagenesis. HIV regions amplified
include a 1.5 kb region in pol (RT: HIV-1JR-CSF 2493–4023; HIV-
1LAI 2063–3595), a 1.4 kb region including vif and vpr (vif: HIV-1JR-
CSF 4941–6399; HIV-1LAI 4511–5969), and a 900 base region in the
39 viral genome (nef: HIV-1JR-CSF 8722–9634; HIV-1LAI 8328–
9211). Amplification of both RT and nef was used to assess
APOBEC3 hypermutation while vif was amplified to asses
APOBEC3 hypermutation and to confirm the integrity (or
restoration) of the ORF. Primer sequences were as follows: RT
outer forward primer, GCTCTATTAGATACAGGAGC; reverse
primer, CCTAATGCATATTGTGAGTCTG; RT inner forward
primer, GTAGGACCTACACCTGTCAAC; reverse primer,
CCTGCAAAGCTAGGTGAATTGC. Vif outer forward primer,
CAGGGACAACAGAGATCC; reverse primer, GTGGGTACA-
CAGGCATGTGTGG; vif inner forward primer, CTTTGGAA
AGGACCAGCAAAGC; reverse primer, GATGCACAAAATA-
GAGTGGTGG. Nef outer forward primer, GAATAGTGCTGT-
TAGCTTGC; reverse primer, CTCAAGGCAAGCTTTATT-
GAGG; nef inner forward primer, TAGAGCTATT-
CGCCACATACC; nef inner reverse, CTTTATTGAGGCT-
TAAGCAGTGG. Amplified viral DNA was sequenced and
compared to the corresponding proviral DNA sequence used to
generate the viruses using the Highlighter sequence visualization tool
(www.hiv.lanl.gov).
Statistics
One-way ANOVA with Bonferroni’s multiple comparison test
(alpha level, 0.01), Paired two-tailed t tests, and Unpaired two-
tailed t tests were all performed using Prism version 4 (Graph Pad,
La Jolla, CA). All data were plotted as mean +/2 SEM.
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Accession numbers
The GenBank (http://www.ncbi.nlm.nih.gov/nuccore) acces-
sion numbers for HIV-1JR-CSF and HIV-1LAI are M38429 and
K02013. The GenPept (http://www.ncbi.nlm.nih.gov/protein)
accession numbers for APOBEC3G and APOBEC3F are
NP_068594 and Q8IUX4.
Supporting Information
Figure S1 APOBEC3F expression is reduced in the
thymus. Human A3F mRNA levels from human PBMC
(n = 7), human thymus (n = 6), NSG-BLT humanized mouse
thymus (n = 18), and CD4+ cells from NSG-BLT humanized
mouse lung (n = 6), spleen (n = 7), liver (n = 7) were determined
using qRT-PCR and normalized to human TATA Box binding
protein. Hatched bars represent human cells; open bars represent
humanized mouse cells. NS = not significant, *** p,0.01 by
one way ANOVA with Bonferroni’s posttest. Data represent
mean +/2 SEM.
(EPS)
Figure S2 The transient replication of CCR5-tropic
HIV-1 lacking vif. Plasma viral load was monitored in NSG-
BLT humanized mice injected directly into the thymus with
3.66105 TCIU of HIVJR-CSFDvif. Viral RNA was transiently
present in the blood of 2/6 mice.
(EPS)
Figure S3 Disruption of vif in HIV-1LAI does not affect
viral replication in the absence of APOBEC3. Spreading
infection cultures with HIVLAI and HIVLAIDvif in CEM-SS cells.
Culture supernatant was assayed for p24Gag by ELISA at three
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